Program
23-valent pneumococcal capsular polysaccharide vaccine
Also written as “PPV23”, “23-valent pneumococcal polysaccharide vaccine” and “Pneumovax™ 23”.
Its studies are mostly in Pneumococcal Infections · Influenza, Human · Diphtheria · Pneumonia, Pneumococcal · Whooping Cough, led by 8 companies.
Drug page23-valent pneumococcal capsular polysaccharide vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 39 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 50 open or running | phase 4since Oct 6, 2014 | Jul 3, 2007 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 4since Feb 20, 2014 | Mar 24, 2006 | none ahead |
| Sinopharmits history only | 20 open or running | phase 4since Jan 6, 2021 | Jan 6, 2021 | none ahead |
| Aimei Vacin BioPharm (Zhejiang)its history only | 11 open or running | phase 3since Sep 13, 2023 | Sep 13, 2023 | none ahead |
| Chongqing Zhifei Biological Productsits history only | 10 open or running | phase 3since Feb 18, 2020 | Feb 18, 2020 | none ahead |
| Pfizerits history only | 10 open or running | phase 4since Aug 21, 2006 | Aug 21, 2006 | none ahead |
| Sanofi | 10 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Sinovac Biotechits history only | 10 open or running | phase 4since Jul 13, 2022 | Jul 13, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2007First study: phase 3 study in Streptococcus PneumoniaeFirst studyNCT00594347 · 339 enrolled · Thailand
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00594347Streptococcus Pneumoniae · Thailand | 3 | Completed | Mar 2008 | 339 |
How it is read
Names in the registry
- “PPV23”, 3 entries
- “23-valent pneumococcal polysaccharide vaccine”, 3 entries
- “Pneumovax™ 23”, 3 entries
- “Pneumo 23”, 2 entries
- “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 6 studies
- Influenza, Human, 2 studies
- Diphtheria, 1 study
- Pneumonia, Pneumococcal, 1 study
- Whooping Cough, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.